List of works - Tjeerd Barf

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

scholarly article

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

scientific article published on 7 September 2017

Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

scientific article published on 20 January 2006

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

scientific article published in August 2002

Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance

scientific article

Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis

scientific article published on 25 June 2020

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.

scientific article

Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target

scientific article published in September 2004

Discovery of quinoline-based irreversible BTK inhibitors

scientific article published on 13 May 2020

Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.

scientific article

Intervention of hepatic glucose production. Small molecule regulators of potential targets for Type 2 diabetes therapy

scientific article

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks ⬇️

scientific article published on 08 June 2012

N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors

scientific article

Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series ⬇️

scientific article published on November 3, 2011

Structure-based lead identification of ATP-competitive MK2 inhibitors ⬇️

scientific article published on April 16, 2011

Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors

scientific article published in September 2004

Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B

scientific article

List of works by Tjeerd Barf

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance

Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.

Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target

Discovery of quinoline-based irreversible BTK inhibitors

Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.

Intervention of hepatic glucose production. Small molecule regulators of potential targets for Type 2 diabetes therapy

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks ⬇️

N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors

Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series ⬇️

Structure-based lead identification of ATP-competitive MK2 inhibitors ⬇️

Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors

Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B